Skip to main content

Venture Capital Firm  I  Home

Innovation.
Clarity.
Execution.

A Venture Capital Firm for Visionary Innovators.

Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.

We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.

We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
About

As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.

We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.
Team

Innovation.

We are backing exceptional innovation early.

Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.

As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.

Portfolio

Latest Press Releases

21 February 2024 in Aleta Biotherapeutics, Press Release, Private Companies

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial

Press Release.   Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies  …
Read More
24 January 2024 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

Press Release.   Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders   First demonstration of efficacy in disease-relevant in…
Read More
18 January 2024 in Orphalan, Press Release, Private Companies

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease

Press Release.   Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January, 2024 - Orphalan SA (“Orphalan” or “the…
Read More

About

Leading Venture Investors
Learn More

Portfolio

Innovative Life Sciences Companies
Learn More